Abstract:Background Overexpression of Aurora A and B has been reported in a wide range of tumor types, including gastric cancer. Anti-angiogenesis has been considered as an important therapeutic modality in advanced gastric cancer. Here we identified a novel compound TY-011 with promising antitumor activity by targeting mitotic kinases (Aurora A and B) and angiogenic receptor tyrosine kinase (VEGFR2). Methods HTRF® KinEASE™ assay was used to detect the effect of TY-011 against Aurora A, Aurora B and VEGFR2 activities. Docking simulation study was performed to predict the binding mode of TY-011 with Aurora A and B kinases. CCK-8 assay was used to test cell growth. Cell cycle and cell apoptosis was analyzed by flow cytometry. Gastric cancer cell xenograft mouse models were used for in vivo study. TUNEL kit was used to determine the apoptosis of tumor tissues. Immunohistochemistry analysis and HUVEC tube formation assay were performed to determine the anti-angiogenesis ability. Immunofluorescence and western blot were used to test protein expression. Results TY-011 was identified as a potential Aurora A and B inhibitor by HTRF® KinEASE™ assay. It effectively inhibited cellular Aurora A and B activities in a concentration-dependent manner. TY-011 occupied the ATP-binding site of both Aurora A and B kinases. TY-011 demonstrated prominent inhibitory effects on proliferation of gastric cancer cells. TY-011 treatment induced an obvious accumulation of cells at G2/M phase and a modest increase of cells with >4 N DNA content, which then underwent apoptosis. Meaningfully, orally administration of TY-011 demonstrated superior efficacy against the tumor growth in gastric cancer cell xenograft, with ~90% inhibition rate and 100% tumor regression at 9 mg/kg dose, and TY-011 did not affect the body weight of mice. Interestingly, we observed that TY-011 also antagonized tumor angiogenesis by targeting VEGFR2 kinase. Conclusions These results indicate that TY-011 is a well-tolerated, orally active compound that targets mitosis and angiogenesis in tumor growth, and provides strong preclinical support for use as a therapeutic for human gastric cancers.

Aurora kinase small molecule inhibitor destroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells.

Aurora Kinase Inhibitory VX-680 Increases Bax/Bcl-2 Ratio and Induces Apoptosis in Aurora-A-high Acute Myeloid Leukemia.

VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma.

Inhibition of Aurora-A Results in Increased Cell Death in 3-Dimensional Culture Microenvironment, Reduced Migration and is Associated with Enhanced Radiosensitivity in Human Nasopharyngeal Carcinoma

Inhibition of Mitotic Kinase Aurora Suppresses Akt-1 Activation and Induces Apoptotic Cell Death in All-Trans Retinoid Acid-Resistant Acute Promyelocytic Leukemia Cells

Aurora-A down-regulates IkappaBα via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival

Aurora A Is Essential for Early Embryonic Development and Tumor Suppression

Effect of Aurora Inhibitor VX-680 on Proliferation and Apoptosis of CML Cells

Inhibition of Aurora A Promotes Chemosensitivity Via Inducing Cell Cycle Arrest and Apoptosis in Cervical Cancer Cells.

The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma.

Aurora-A, A Negative Prognostic Marker, Increases Migration and Decreases Radiosensitivity in Cancer Cells

Targeting Aurora B Kinase with Tanshinone IIA Suppresses Tumor Growth and Overcomes Radioresistance

Aurora B Kinase As a Novel Molecular Approach for Osteosarcoma Therapy

Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer Growth.

Aurora B kinase as a novel molecular target for inhibition the growth of osteosarcoma.

Orally Active Aurora A/B Kinase Inhibitor, AM‐005, Suppresses the Growth of Human Colon Carcinoma Cells

Overexpression of Aurora-A Kinase Promotes Tumor Cell Proliferation and Inhibits Apoptosis in Esophageal Squamous Cell Carcinoma Cell Line.

Inhibition of Aurora-A Suppresses Epithelial-Mesenchymal Transition and Invasion by Downregulating MAPK in Nasopharyngeal Carcinoma Cells.

Stable knockdown of Aurora-A by vector-based RNA interference in human esophageal squamous cell carcinoma cell line inhibits tumor cell proliferation, invasion and enhances apoptosis.

Oxethazaine inhibits esophageal squamous cell carcinoma proliferation and metastasis by targeting aurora kinase A

Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases